Tucidinostat (Synonyms: Chidamide; HBI-8000; CS 055)

Name: Tucidinostat
Brand: MedChemExpress
SKU: HY-109015
Rating: 5.0 (29 reviews)

Cat. No.: HY-109015 Purity: 98.60%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC₅₀s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.

For research use only. We do not sell to patients.

Tucidinostat Chemical Structure

CAS No. : 1616493-44-7

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Tucidinostat:

Tucidinostat-d₄ In-stock
Tucidinostat (Standard) Get quote

29 Publications Citing Use of MCE Tucidinostat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Isoforms

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

HDAC3

67 nM (IC₅₀)

HDAC10

78 nM (IC₅₀)

HDAC1

95 nM (IC₅₀)

HDAC2

160 nM (IC₅₀)

HDAC11

432 nM (IC₅₀)

HDAC8

733 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.63 μM Compound: chidamide	Antiproliferative activity against human 786-O cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human 786-O cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
A549	IC₅₀	2.79 μM Compound: chidamide	Antiproliferative activity against human A549 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human A549 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
A549	IC₅₀	9.85 μM Compound: 6; CS005	Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
A549	IC₅₀	9432 nM Compound: 5	Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
CAKI-1	IC₅₀	570 nM Compound: 5	Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
CCRF-CEM	IC₅₀	0.63 μM Compound: Chidamide	Cytotoxicity against human CCRF-CEM cells by MTT assay Cytotoxicity against human CCRF-CEM cells by MTT assay	[PMID: 31078410]
CCRF-CEM	IC₅₀	0.83 μM Compound: chidamide	Antiproliferative activity against human CCRF-CEM cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human CCRF-CEM cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
CCRF-CEM	IC₅₀	1 μM Compound: Chidamide	Cytotoxicity against human CCRF-CEM cells measured after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells measured after 72 hrs by MTT assay	[PMID: 34986303]
COLO-678	IC₅₀	> 10 μM Compound: chidamide	Antiproliferative activity against human COLO-678 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human COLO-678 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
CWR22R	IC₅₀	1.08 μM Compound: chidamide	Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
DOHH-2	IC₅₀	0.53 μM Compound: chidamide	Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
DOHH-2	IC₅₀	449 nM Compound: 5	Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
DU-145	IC₅₀	1.49 μM Compound: 6; CS005	Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
EBC-1	IC₅₀	2.9 μM Compound: CS-055	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	[PMID: 28835797]
ES-2	IC₅₀	669 nM Compound: 5	Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	0.34 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HCT-116	IC₅₀	0.92 μM Compound: 6; CS005	Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HCT-116	IC₅₀	1.09 μM Compound: HBI-8000; CS055	Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
HCT-116	IC₅₀	1.18 μM Compound: 5	Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	2.08 μM Compound: Chidamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
HCT-116	IC₅₀	2.08 μM Compound: chidamide	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
HCT-116	IC₅₀	2.082 μM Compound: Chidamide	Antiproliferative activity against human HCT-116 cells assessed as cell viability at 1 uM incubated for 72 hrs by luminescence assay Antiproliferative activity against human HCT-116 cells assessed as cell viability at 1 uM incubated for 72 hrs by luminescence assay	[PMID: 34995925]
HCT-116	IC₅₀	7.8 μM Compound: CS-055	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 28835797]
HCT-116	IC₅₀	> 20 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HCT116 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HEK293	IC₅₀	6244 nM Compound: 5	Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HEL	IC₅₀	0.013 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HEL cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HEL cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HEL	IC₅₀	1.8 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HEL cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HEL cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HL-60	IC₅₀	0.0022 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HL-60	IC₅₀	1.97 μM Compound: HBI-8000; CS055	Antiproliferative activity against human HL60 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human HL60 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
HL-60	IC₅₀	3.11 μM Compound: Chidamide	Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
HL-60	IC₅₀	3.2 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HL60 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HT-29	IC₅₀	4.57 μM Compound: 6; CS005	Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HT-29	IC₅₀	6.04 μM Compound: chidamide	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
HeLa	IC₅₀	2623 nM Compound: 5	Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HeLa	IC₅₀	7.16 μM Compound: CS055, Epidaza	Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay	10.1039/C4MD00350K
HepG2	IC₅₀	2 μM Compound: Chidamide	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
HepG2	IC₅₀	4.89 μM Compound: 2	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
HuT78	IC₅₀	2.42 μM Compound: chidamide	Antiproliferative activity against human HuT78 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HuT78 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
Jurkat	IC₅₀	1202 nM Compound: 5	Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
K562	IC₅₀	0.32 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
K562	IC₅₀	0.747 μM Compound: HBI-8000; CS055	Antiproliferative activity against human K562 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human K562 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
K562	IC₅₀	0.87 μM Compound: 2	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
K562	IC₅₀	1.34 μM Compound: Chidamide	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 31078410]
K562	IC₅₀	1775 nM Compound: 5	Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
K562	IC₅₀	2.4 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human K562 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
K562	IC₅₀	8.3 μM Compound: Chidamide	Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 34986303]
Kasumi 1	IC₅₀	> 10 μM Compound: Chidamide	Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
LNCaP	IC₅₀	2.89 μM Compound: 6; CS005	Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MC-38	IC₅₀	3.3 μM Compound: 5	Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MCF7	IC₅₀	29.07 μM Compound: HBI-8000; CS055	Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
MCF7	IC₅₀	> 20 μM Compound: 6; CS005	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-231	IC₅₀	1.86 μM Compound: 6; CS005	Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-231	IC₅₀	619 nM Compound: 5	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MDA-MB-231	IC₅₀	9.52 μM Compound: chidamide	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
MDA-MB-468	IC₅₀	2.65 μM Compound: 2	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
MIA PaCa-2	IC₅₀	1682 nM Compound: 5	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MOLT-4	IC₅₀	0.75 μM Compound: chidamide	Antiproliferative activity against human MOLT-4 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human MOLT-4 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
MV4-11	IC₅₀	0.783 μM Compound: Chidamide	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
MV4-11	IC₅₀	3.73 μM Compound: 2	Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
NCI-H1650	IC₅₀	> 20 μM Compound: 6; CS005	Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H441	IC₅₀	2.62 μM Compound: chidamide	Antiproliferative activity against human NCI-H441 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human NCI-H441 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
NCI-H446	IC₅₀	0.24 μM Compound: 6; CS005	Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H460	IC₅₀	2.34 μM Compound: chidamide	Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
NCI-N87	IC₅₀	4515 nM Compound: 5	Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	3091 nM Compound: 5	Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	5.77 μM Compound: 6; CS005	Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
PC-9	IC₅₀	1714 nM Compound: 5	Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
RS4-11	IC₅₀	0.6 μM Compound: chidamide	Antiproliferative activity against human RS4-11 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human RS4-11 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
Rec1	IC₅₀	1.01 μM Compound: chidamide	Antiproliferative activity against human REC1 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human REC1 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
SK-OV-3	IC₅₀	8.46 μM Compound: chidamide	Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
SKM-1	IC₅₀	549 nM Compound: CS055	Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay	[PMID: 37184921]
SU-DHL-2	IC₅₀	0.56 μM Compound: chidamide	Antiproliferative activity against human SUDHL2 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human SUDHL2 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
Sf9	IC₅₀	0.167 μM Compound: 2	Inhibition of recombinant full-length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay Inhibition of recombinant full-length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay	[PMID: 31053508]
TMD8	IC₅₀	0.48 μM Compound: chidamide	Antiproliferative activity against human TMD8 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human TMD8 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
U-937	IC₅₀	3.3 μM Compound: Chidamide	Cytotoxicity against human U-937 cells measured after 72 hrs by MTT assay Cytotoxicity against human U-937 cells measured after 72 hrs by MTT assay	[PMID: 34986303]
U-937	IC₅₀	4.66 μM Compound: Chidamide	Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
ZR-75-1	IC₅₀	> 10000 nM Compound: 5	Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]

In Vitro

Tucidinostat (Chidamide/CS055/HBI-8000) is a potent and orally bioavailable HDAC enzymes class I (HDAC1, 2, 3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC₅₀s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9 (IC₅₀s, >30 μM). Tucidinostat shows potent antitumor activity, and inhibits several human derived tumor cell lines, such as HL-60, U2OS, LNCaP with GI₅₀s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tucidinostat (12.5-50 mg/kg, p.o.) dose-dependently reduces tumor size and tumor weight in mice bearing HCT-8 colorectal carcinoma, A549 lung carcinoma, BEL-7402 liver carcinoma, and MCF-7 breast carcinoma, and with no obvious body loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

390.41

Formula

C₂₂H₁₉FN₄O₂

CAS No.

1616493-44-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=C(CNC(/C=C/C2=CN=CC=C2)=O)C=C1)NC(C=CC(F)=C3)=C3N

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (128.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 1 mg/mL (2.56 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5614 mL	12.8070 mL	25.6141 mL
5 mM	0.5123 mL	2.5614 mL	5.1228 mL
10 mM	0.2561 mL	1.2807 mL	2.5614 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.60%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (246 KB) HNMR (263 KB) RP-HPLC (243 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Ning ZQ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.5614 mL	12.8070 mL	25.6141 mL	64.0352 mL
DMSO	5 mM	0.5123 mL	2.5614 mL	5.1228 mL	12.8070 mL
	10 mM	0.2561 mL	1.2807 mL	2.5614 mL	6.4035 mL
	15 mM	0.1708 mL	0.8538 mL	1.7076 mL	4.2690 mL
	20 mM	0.1281 mL	0.6404 mL	1.2807 mL	3.2018 mL
	25 mM	0.1025 mL	0.5123 mL	1.0246 mL	2.5614 mL
	30 mM	0.0854 mL	0.4269 mL	0.8538 mL	2.1345 mL
	40 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6009 mL
	50 mM	0.0512 mL	0.2561 mL	0.5123 mL	1.2807 mL
	60 mM	0.0427 mL	0.2135 mL	0.4269 mL	1.0673 mL
	80 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8004 mL
	100 mM	0.0256 mL	0.1281 mL	0.2561 mL	0.6404 mL

Tucidinostat Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tucidinostat1616493-44-7Chidamide HBI-8000 CS 055HBI8000HBI 8000HBI-8000CS055CS 055CS-055HDACHistone deacetylasesInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tucidinostat (Synonyms: Chidamide; HBI-8000; CS 055)

Customer Review

Other Forms of Tucidinostat:

Tucidinostat Related Antibodies

29 Publications Citing Use of MCE Tucidinostat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Tucidinostat Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tucidinostat Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report